Comparing Protease Combinations
From Treatment Action Group
May 1996
Reported maximum average reductions in plasma
RNA with selected protease inhibitor combinations
(in treament naive/experienced* individuals)
|
| SQV |
.6 log |
S. Vella
|
| SQV(new formulation) |
1.5 log |
Roche
|
| RTV |
1.2-1.9 log |
Abbott
|
| IDV |
1.2-2.0 log |
Merck
|
| NFV |
1.5 log |
Markowitz
|
| SQV+AZT |
1.0 log |
S. Vella
|
| SQV+ddC |
.6 log |
Roche NV*
|
| SQV+AZT+ddC |
.8 log |
ACTG 229*
|
| RTV+AZT |
1.2 log |
Abbott
|
| RTV+AZT+ddC |
2.0-2.5 log |
Leibowich
|
| IDV+AZT |
1.4-1.5 log |
Merck
|
| IDV+AZT+ddl |
2.9 log |
Merck
|
| IDV+AZT3TC |
>2.0 log |
Merck 035*
|
| NFV+d4T |
2.4-2.6 log |
Chapman
|
This article was provided by Treatment Action Group. It is a part of the publication TAGline.
Email
Print-Friendly
Glossary
